An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
VERDICT
The label
Markup
read at $42.32
Eton Pharmaceuticals, Inc. holds its Markup at $42.32.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 2 days
Price
$42.32
Valuation
N/A trailing · 22.51 forward price to earnings
Values screen
PASS· score 97.4
Beta
0.86
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads OPPORTUNITY — it trades at roughly a 6% discount to our $44.93 fair value, weak competitive moat, 40.40% revenue growth.
Read at
$42.32
N/A P/E · 22.51 fwd
Our fair value
$44.93
6% discount
Analyst target (avg)
$48.50
+15% to current
Target low $40.00Analyst target rangeTarget high $60.00
▲ current $42.32 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$42.32
you are here
Conservative
$36.00
-15%
Analyst avg
$48.50
+15%
Our fair value
$44.93
+6%
Analyst high
$60.00
+42%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
40.40%
Profit margin
-1.70%
Debt to equity
102.11
Analyst consensus
Strong Buy · 4 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 3.8% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 3.2% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 0.0% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Every family chasing treatment for a rare growth disorder or adrenal shortfall ends up relying on smaller players like Eton that fill gaps left by big pharma. Revenue is climbing 40% as the firm commercialises products such as Increlex and Alkindi Sprinkle, yet it still runs at a 2% negative profit margin and negative 5% ROE. At 22.5 times forward earnings the shares sit just below our fair value of 44.93 against a 42.32 price, and the ethical screen clears cleanly.
The business model hinges on orphan-drug niches where competition stays limited for now, and four analysts carry a strong-buy consensus with a 48 median target. Weak moat leaves room for larger entrants, but the growth trajectory and positive margin of safety mark a clear opportunity versus broader sector names.
Execution risk remains high while losses persist and returns on equity stay negative. Any delay in new launches or reimbursement pressure could widen those gaps quickly. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in ETON's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
ETON trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 45.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 60% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 100%. Our forward projection puts the odds of a 10% gain over the next month near 53%. The street (3 analysts) rates it strong buy, with a mean price target of $43. Entered 2026-07-28 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-28Markup$42.32+45.3%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 45.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 60% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 100%. Our forward projection puts the odds of a 10% gain over the next month near 53%. The street (3 analysts) rates it strong buy, with a mean price target of $43.
2026-07-18Markup$29.13+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 60% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 100%. Our forward projection puts the odds of a 10% gain over the next month near 53%. The street (3 analysts) rates it strong buy, with a mean price target of $43.
2026-07-03Markup$29.13+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (97). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$29.13Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (97). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
INSIDERS
The insider ledger · Form 4 filings, as filed
Most recent filings · ETON
Date
Insider
Title
Type
Shares
Value
2026-04-21
RIEDEL NORBERT G
Director
32,155
$260,605
2026-02-03
RIEDEL NORBERT G
Director
30,000
$132,600
2025-08-20
GRUBER JAMES R
Chief Financial Officer
41,713
$673,714
2025-06-16
KREMPA DAVID
Officer
34,000
$504,318
2025-06-10
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
7,930
$125,484
2025-06-05
BRYNJELSEN SEAN E
Chief Executive Officer
210,000
$3,592,611
2025-01-03
RIEDEL NORBERT G
Director
102,400
$373,842
2024-10-23
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
10,000
$79,814
2024-10-08
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
62,070
$434,137
2024-09-11
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
